TICKERNERD
Menu
ACONACONHealthcare · Health Information Services

ACON Stock Forecast: Aclarion, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$2.36
+4.89% on the day

The 1 Wall Street analysts covering Aclarion, Inc. hold a median 12-month price target of $7.5 — +217.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.5M
Ticker Nerd rank
23 / 100
Median analyst target
$7.50
Analysts covering
1
Total return, dividends reinvested
1W
+6.3%
1M
−23.6%
YTD
−48.7%
1Y
−66.3%
From 52W high
−75.6%
From 52W low
+17.1%
$2.02
$9.69
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACON stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aclarion, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Growth
54
Accruals
50
Volatility
42
Quality
34
Revisions
32
Momentum
30
Issuance
24
Value
2

Size (95): Smaller than most of the companies we track.

Value (2): The shares cost a lot relative to the profits and assets behind them.

The rank is the raw material. Whether the rules would actually own Aclarion, Inc. — and when they’d sell — is the membership.

Wall Street

ACON stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACON, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26ACONHigh $7.50Median $7.50Low $7.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $7.50Median $7.50High $7.50

The green dot is the last close — the median target sits +217.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 May 2026Ascendiant CapitalMaintainsBuy$7.00 → $7.50
25 Mar 2026Ascendiant CapitalMaintainsBuy—
20 Nov 2025Ascendiant CapitalMaintainsBuy—
19 Sept 2025Ascendiant CapitalMaintainsBuy—
13 Dec 2024Maxim GroupDowngradeHold—
27 Nov 2024Ascendiant CapitalMaintainsBuy—
26 Aug 2024Ascendiant CapitalMaintainsBuy—
29 July 2024Ascendiant CapitalInitiatesBuy—
6 July 2022Maxim GroupInitiatesBuy$3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ACON analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Aclarion, Inc. (ACON) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 77% of US stocks

Price / sales
74.6×

Cheaper than 4% of US stocks

Price / book
0.3×

Cheaper than 88% of US stocks

EV / EBITDA
1.6×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
11.3%

Higher than 58% of US stocks

Earnings growth (YoY)
11.3%

Higher than 52% of US stocks

Gross margin
17.7%

Higher than 19% of US stocks

Operating margin
−14129.3%

Higher than 2% of US stocks

Net margin
9.0%

Higher than 68% of US stocks

Returns & dividend
Return on equity
−45.4%

Higher than 22% of US stocks

Return on assets
−28.8%

Higher than 15% of US stocks

Dividend yield
170.2%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ACON vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
ACONAclarion, Inc.$5.5M
23
VSEEVSee Health, Inc.$4.4M
31
MGRXMangoceuticals, Inc.$9.6M
25
BFRGBullFrog AI Holdings, Inc.$10.2M
29
MNDRMobile-health Network Solutions$2.2M
14
HCTIHealthcare Triangle, Inc.$2.2M
20
ZCMDZhongchao, Inc.$1.3M
22
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACON appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ACON news & analysis

Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026

GlobeNewsWire · 29 July 2026positive

Aclarion published a shareholder letter from CEO Brent Ness updating shareholders on the company's progress in the first half of 2026, citing 141% year-over-year scan volume growth, a newly launched U.S. Market Access Program with PRIA Healthcare, and a strengthened IP portfolio with 65 patents.

Why it matters — ACON watchers would care because the letter provides a direct update from management on operational milestones including scan volume growth, U.S. reimbursement efforts, and trial progress.

FAQ

Frequently asked questions about ACON stock

What is the ACON stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Aclarion, Inc. have a median 12-month price target of $7.5, with estimates ranging from $7.5 to $7.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACON stock a buy right now?

Of the 1 analysts covering Aclarion, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aclarion, Inc. 23 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACON?

As at 1 Aug 2026, Aclarion, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

Will ACON stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +217.8% from the last close, and Ticker Nerd's factor model ranks Aclarion, Inc. 23 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACON stock forecast for 2030?

No analyst covering Aclarion, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7.5 to $7.5 over the next 12 months.

How has ACON stock performed over the past year?

Aclarion, Inc. returned -66.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aclarion, Inc. do?

Aclarion Inc. is a healthcare technology company that develops innovative diagnostic solutions for spine-related conditions, particularly low back and neck pain.

What is the latest news on ACON?

The most recent item we track (GlobeNewsWire, 29 July 2026): "Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026". Aclarion published a shareholder letter from CEO Brent Ness updating shareholders on the company's progress in the first half of 2026, citing 141% year-over-year scan volume growth, a newly launched U.S. Market Access Program with PRIA Healthcare, and a strengthened IP portfolio with 65 patents.

Company

About Aclarion, Inc.

Aclarion Inc. is a healthcare technology company that develops innovative diagnostic solutions for spine-related conditions, particularly low back and neck pain. The company combines magnetic resonance spectroscopy (MRS) imaging with proprietary augmented-intelligence algorithms to create software-as-a-service (SaaS) solutions that help physicians personalize treatment plans and optimize clinical outcomes. The company's primary offering is the NOCISCAN Suite, which uses MRS capabilities to noninvasively analyze the chemical composition of intervertebral discs in the spine. Aclarion's suite includes the NOCISCAN MRS Exam Protocol for standard lumbar MRI exams, the NOCISCAN Post-Processor Suite with NOCICALC and NOCIGRAM applications that process spectroscopy data and calculate degenerative pain biomarkers, and complementary imaging data transfer platforms. By leveraging artificial intelligence to assist in quality control processes and proprietary biomarkers, Aclarion aims to address unmet clinical needs in musculoskeletal pain management and help patients achieve improved health outcomes and pain relief.

CEO Mr. Brent Ness · 10 employees · United States · https://www.aclarion.com